Erratum: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987 (Journal of Clinical Oncology DOI: 10.1200/JCO.2011.38.6979);Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987

Journal of Clinical Oncology

Volumn 30, Issue 10, 2012, Pages 1107-1113

  Bellmunt, Joaquim ^a   Von Der Maase, Hans ^c,d   Mead, Graham M ^e   Skoneczna, Iwona ^f   De Santis, Maria ^g   Daugaard, Gedske ^d   Boehle, Andreas ^h   Chevreau, Christine ⁱ   Paz Ares, Luis ^b   Laufman, Leslie R ^j   Winquist, Eric ^k   Raghavan, Derek ^k   Marreaud, Sandrine ^l   Collette, Sandra ^l   Sylvester, Richard ^l   De Wit, Ronald ^m,n  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g KAISER FRANZ JOSEF HOSPITAL   (Austria)

^h HELIOS AGNES KARLL HOSPITAL   (Germany)

ⁱ INSTITUT CLAUDIUS REGAUD   (France)

^j Blood and Cancer Care of Ohio   (United States)

^k LEVINE CANCER INSTITUTE   (United States)

^l UNIVERSITY OF WESTERN ONTARIO   (Canada)

^m EORTC DATA CENTER   (Belgium)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; ADVANCED UROTHELIAL CARCINOMA; AGED; ALOPECIA; ARTICLE; ASTHENIA; BLADDER CARCINOMA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; KIDNEY PELVIS CARCINOMA; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTATIC UROTHELIAL CARCINOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URETER CARCINOMA; URETHRA CARCINOMA;

EID: 84863897662     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2018.78.0759     Document Type: Erratum

References (26)

1. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989 (Pubitemid 20014925)
2. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
3. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
4. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990 (Pubitemid 20200193)
5. Bellmunt J, Ribas A, Eres N, et al: Carboplatinbased versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966-1972, 1997 (Pubitemid 27479792)
6. Loehrer PJ Sr, Elson P, Dreicer R, et al: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colonystimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 12:483-488, 1994
7. Logothetis CJ, Finn LD, Smith T, et al: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol 13:2272-2277, 1995
8. Seidman AD, Scher HI, Gabrilove JL, et al: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408-414, 1993 (Pubitemid 23071035)
9. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270, 1994 (Pubitemid 24346693)
10. Lorusso V, Pollera CF, Antimi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum: Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34:1208-1212, 1998 (Pubitemid 28342111)
11. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441- 3445, 1997
12. Pollera CF, Ceribelli A, Crecco M, et al: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184, 1994 (Pubitemid 24062575)
13. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997 (Pubitemid 27485860)
14. Bellmunt J, Albanell J, Paz-Ares L, et al: Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95:751-757, 2002 (Pubitemid 34839666)
15. Bellmunt J, Guillem V, Paz-Ares L, et al: Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium: Spanish Oncology Genitourinary Group. J Clin Oncol 18:3247-3255, 2000
16. Bellmunt J,0 0 von der Maase H, Mead GM, et al: Randomized phase III study comparing paclitaxel/ cisplatin/gemcitabine (PCG) and gemcitabine/ cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J Clin Oncol 25:242s, 2007 (suppl; abstr LBA5030)
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Therasse P, Eisenhauer EA, Verweij J: RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 42:1031-1039, 2006
19. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999 (Pubitemid 29470648)
20. Akdogan B, Dogan HS, Eskicorapci SY, et al: Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. J Urol 176:48-52, 2006 (Pubitemid 43815384)
21. Cuckow PM, Nyirady P, Winyard PJ: Normal and abnormal development of the urogenital tract. Prenat Diagn 21:908-916, 2001 (Pubitemid 33140164)
22. Riedel I, Liang FX, Deng FM, et al: Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: Different degrees of urothelial maturity in ureter and bladder? Eur J Cell Biol 84:393-405, 2005 (Pubitemid 40353077)
23. Hudson AE, Feng WC, Delostrinos CF, et al: Spreading of embryologically distinct urothelial cells is inhibited by SPARC. J Cell Physiol 202:453-463, 2005 (Pubitemid 40041315)
24. Catto JW, Azzouzi AR, Amira N, et al: Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 22:8699-8706, 2003 (Pubitemid 38010493)
25. Hartmann A, Zanardo L, Bocker-Edmonston T, et al: Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res 62: 6796-6802, 2002 (Pubitemid 35424061)
26. Catto JW, Azzouzi AR, Rehman I, et al: Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23:2903-2910, 2005 (Pubitemid 46224108)